Cagrilintide and Semaglutide (CagriSema) 5mg/5mg Lyophilized Vial
Cagrilintide and Semaglutide, collectively referred to as CagriSema, is a research-grade dual-agonist peptide blend designed for metabolic health and weight management. This powerful combination includes an acylated amylin analogue (Cagrilintide) and a GLP-1 receptor agonist (Semaglutide) to enhance satiety and regulate appetite effectively.
Key Features
- Research-grade peptide blend (batch-tested purity)
- Combines Cagrilintide (coordinated gastric emptying) and Semaglutide (GLP-1 mimicking) for enhanced weight management
- Promotes significant weight loss and better metabolic health in research settings
- Supplied lyophilized for investigator-controlled reconstitution and dosing
- Typical format: 5mg Cagrilintide and 5mg Semaglutide per vial for research use
Product Specifications
- Product Name: Cagrilintide and Semaglutide (CagriSema) Blend (5 mg + 5 mg) (Purity: >99+% HPLC)
- Category: Metabolic health research compound
- Supplied in: Lyophilized powder in sterile vial + 3ml bac water
- Typical Administration (Research): Subcutaneous injection (as per study protocol)
- Storage (Reconstituted): Refrigerate at 2–8 °C; use within 30 days; avoid freeze-thaw cycles
Mechanism of Action
Cagrilintide and Semaglutide engage dual physiological pathways. Cagrilintide activates amylin receptors to slow gastric emptying and signal fullness, while Semaglutide mimics GLP-1 to enhance satiety and reduce food intake. This combined activity results in greater metabolic control and weight loss efficacy compared to using either peptide alone.
Potential Research Applications
- Weight management and obesity treatment studies
- Investigating appetite regulation and satiety mechanisms
- Metabolic health and insulin sensitivity research
- Endocrinology and diabetes model evaluations
- Preclinical studies assessing dual-agonist therapies
Suggested Research Notes & Dosing Context
- Reconstitution: Reconstitute with 3 mL of Bacteriostatic Water (BAC) to the 5mg/5mg lyophilized vial.
- Dosing:
- Starting Dose: It is commonly recommended to initiate treatment with a lower dose of 1.25 mg (0.625 mg each of Cagrilintide and Semaglutide) per week, depending on individual tolerance and study protocol.
- Titration: The dosage may be gradually increased to a target maintenance dose of up to 2.5 mg (1.25 mg of each compound) per week.
- Administration Example: Administer the entire reconstituted 5mg vial over the week, adjusting according to participant needs and specific study objectives.
- Missed Dose: If a dose is missed, it should be administered as soon as possible within 3 days (72 hours) of the missed dose.
- Concentration:
- 10 mg total peptide per 3 mL = 3.33 mg/mL.
- Volume for 1 mg: 1 mL / 3.33 = 0.3 mL.
- Volume for 2 mg: 2 × 0.3 mL = 0.6 mL.
- In insulin syringe units (100 units = 1 mL): 0.6 mL = 60 units.
Research Insights
CagriSema effectively activates pathways linked to weight management and metabolic health. With confirmed improvements in body weight and metabolic markers in controlled trials, this combination serves as a valuable tool for exploring dual receptor agonists in research.
Key Weight Loss Results and Timeline for CagriSema
- Average Weight Loss: Participants in the Phase 3 REDEFINE 1 trial experienced an average weight reduction of 20.4% to 22.7% after 68 weeks.
- Extended Timeline: In the REDEFINE 4 trial, extending to 84 weeks, CagriSema led to approximately 23% weight loss.
- High Responders: Nearly 60% of participants in some trials achieved a weight loss of 20% or more, while over 40% lost 25% or more of their body weight.
- Comparison to Wegovy: CagriSema demonstrated greater efficacy compared to semaglutide (Wegovy) alone, which typically led to lower percentage weight losses in similar trials.
Key Findings (2026 Update)
- Type 2 Diabetes: CagriSema produced superior weight loss of up to 14.2% in patients with type 2 diabetes after 68 weeks, as shown in the REIMAGINE 2 trial.
- Composition of Weight Loss: Data indicated that 66.9% of the weight lost was attributed to fat mass, with a total reduction in fat mass of 35.7%.
- Regulatory Status: Novo Nordisk submitted CagriSema for FDA approval in December 2025, with a decision anticipated by late 2026.
Possible Observations and Adverse Events
- Monitor for potential gastrointestinal side effects, including nausea and vomiting.
- Safety profile may vary based on dosage and species in experimental settings.
- Regular assessment of metabolic parameters is recommended.
Storage, Stability, and Handling After Reconstitution
- Store reconstituted solutions in the refrigerator at 2–8 °C and use within 30 days; do not freeze.
- Protect from light and minimize freeze-thaw cycles.
- Employ aseptic techniques during handling.
Safety and Handling
- For laboratory research use only.
- Follow institutional biosafety and chemical handling protocols.
- Use appropriate personal protective equipment (PPE) such as gloves, lab coats, and safety goggles.
- In case of accidental exposure, follow institutional incident procedures.
Legal and Regulatory Notice
By purchasing this product, you confirm that you are using it for lawful research purposes. It is the purchaser's responsibility to ensure compliance with local laws and institutional policies. Liability for misuse is disclaimed.
